Breaking News: The U.S. Food and Drug Administration (FDA) just granted accelerated approval of the drug Northera for its treatment of symptomatic neurogenic orthostatic hypotension (NOH). You may not be aware of this drug, but you may know more about its developer, Chelsea Therapeutics International Ltd. (NASDAQ:CHTP).
The company creates products to treat human diseases, including nervous systems disorders. The exciting accelerated approval of this drug means that Northera could reach the market much sooner than later, treating dizziness and lightheadedness in adult patients suffering diseases such as Parkinson’s. This big news has some analysts eager to recommend BUY Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), while other analysts are taking a more cautious approach to the stock, recommending HOLD CHTP.
Berkshire Hathaway’s Buffett On Diversification
In his 2014 letter preview, Buffett states that, far from being a weak choice, indexing can often achieve investor's goals far more easily than complicated picking strategies. This is a special guest post by Robert R. Johnson, Ph.D., CFA, CAIA. He is a full professor of finance at the Heider College of Business at Creighton Read More
Wedbush analyst Liana Moussatos recommended BUY Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) with and $8.00 price target. Liana believes there is a chance that CHTP could be acquired by another company, however there is a chance that they could launch Northera on their own. “We estimate the company could launch Northera sometime in H2: 14 following the build-out of a commercial infrastructure and manufacturing scale-up. We conservatively project about $430 million in worldwide peak sales potential.” Liana is ranked number 7 out of 2396 analysts and has a 19.3% average return over S&P-500.
Liana also recommended BUY Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) back in January and is already seeing a positive return. Before the FDA issued an accelerated approval of Northera, Liana had a feeling the FDA was leaning towards an approval, “Our impression was that the panel came to appreciate the vagaries of clinical trials for neurological disorders – especially in orphan diseases like NOH.” Liana has already earned +12.4% over S&P-500.
On the other hand, analyst Robyn Karnauskas of Deutsche Bank, recommended HOLD Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), but with the same price target of $8.00. Robyn acknowledged that “there is a real unmet market need,” for Northera. However, she maintains her HOLD recommendation because her “DCF value is close to post market stock value.” Robyn noted, “we would revisit our these if our checks indicated bigger market OPP’Y and/or uptake is brisk.” Robyn is ranked 300 out of 2396 analysts and has a 2.5% average return over S&P-500.